+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06982079

Study of Dapagliflozin to Slow Kidney Decline and Reduce Heart and Kidney Risks in Adults with Advanced Chronic Kidney Disease

Led by Ain Shams University · Updated on 2025-05-21

60

Participants Needed

1

Research Sites

21 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether dapagliflozin can reduce the risk of worsening kidney function or death from heart and kidney causes in adults with advanced chronic kidney disease CKD, including those with or without type 2 diabetes. This Phase 3 trial aims to fill a gap in knowledge since previous studies excluded patients with very low kidney function or those on dialysis. The study focuses on important questions about slowing kidney decline and reducing fatal cardiovascular and renal events in this high-risk group. Participants will be randomly assigned to receive either dapagliflozin 10 mg added to their usual care or standard care alone. The trial compares these two groups to assess if dapagliflozin improves kidney and heart outcomes. The treatment period is planned for at least one year, during which patients continue their regular medical care alongside the study interventions. During the study, participants will have their kidney function monitored through tests measuring the estimated glomerular filtration rate eGFR slope and the timing of any need for kidney replacement therapy. Hospitalizations for heart failure and overall survival will also be tracked. Safety will be assessed regularly, and the total participation time spans at least one year, with ongoing evaluations to understand the impact of dapagliflozin on advanced CKD.

CONDITIONS

Brief Title

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here